A bionic multichannel nanofiber conduit carrying Tubastatin A for repairing injured spinal cord
Source abstract
Abstract
Spinal cord injury is a kind of nerve injury disease with high disability rate. The bioscaffold, which presents a biomimetic structure, can be used as “bridge” to fill the cavity formed by the liquefaction and necrosis of spinal nerve cells, and connects the two ends of the fracture to promote the effective recovery of nerve function. Tubasatin A (TUBA) is a potent selective histone deacetylase 6 (HDAC6) inhibitor, which can inhibit the overexpression of HDAC6 after spinal cord injury. However, TUBA is limited by high efflux ratios, low brain penetration and uptake in the treatment of spinal cord injury. Therefore, an effective carrier with efficient load rate, sustained drug release profile, and prominent repair effect is urgent to be developed. In this study, we have prepared a bionic multichannel Tubasatin A loaded nanofiber conduit (SC-TUBA(+)) through random electrospinning and post-triple network bond crosslinking for inhibiting HDAC6 as well as promoting axonal regeneration during spinal cord injury treatment. The Tubasatin A-loaded nanofibers were shown to be successfully contained in poly(glycolide-co-ε-caprolactone) (PGCL)/silk fibroin (SF) matrix, and the formed PGCL/SF-TUBA nanofibers exhibited an uniform and smooth morphology and appropriate surface wettability. Importantly, the TUBA loaded nanofibers showed a sustained-release profile, and still maintains activity and promoted the extension of axonal. In addition, the total transection large span model of rat back and immunofluorescent labeling, histological, and neurobehavioral analysis were performed for inducing spinal cord injury at T9-10, evaluating therapeutic efficiency of SC-TUBA(+), and elucidating the mechanism of TUBA release system in vivo. All the results demonstrated the significantly reduced glial scar formation, increased nerve fiber number, inhibited inflammation, reduced demyelination and protected bladder tissue of TUBA-loaded nanofibers for spinal cord injury compared to SC-TUBA, SC and Control groups, indicating their great potential for injured spinal cord healing clinically.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nerve injury and regeneration · Histone Deacetylase Inhibitors Research · Spinal Cord Injury Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Current concepts of stem cell therapy for chronic spinal cord injury10.3390/ijms22147435 ↗
2. Intrinsic mechanisms of neuronal axon regeneration10.1038/s41583-018-0001-8 ↗
3. PI 3-kinase delta enhances axonal PIP 3 to support axon regeneration in the adult CNS10.15252/emmm.201911674 ↗
4. Restoring cellular energetics promotes axonal regeneration and functional recovery after spinal cord injury10.1016/j.cmet.2020.02.002 ↗
5. Intrinsic control of axon regeneration10.1016/j.neuron.2016.04.022 ↗
6. New insights into glial scar formation after spinal cord injury
7. The intrinsic axon regenerative properties of mature neurons after injury10.1093/abbs/gmaa148 ↗
8. Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapy10.1016/j.actbio.2021.03.018 ↗
9. 3D bioprinted neural tissue constructs for spinal cord injury repair10.1016/j.biomaterials.2021.120771 ↗
10. NSCs migration promoted and drug delivered exosomes-collagen scaffold via a bio-specific peptide for one-step spinal cord injury repair
11. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A10.1021/ja102758v ↗
12. Histone deacetylase 6 inhibition restores autophagic flux to promote functional recovery after spinal cord injury10.1016/j.expneurol.2019.113138 ↗
13. Histone deacetylase inhibition rescues maternal deprivation-induced GABAergic metaplasticity through restoration of AKAP signaling10.1016/j.neuron.2015.05.024 ↗
14. Histone deacetylase inhibition reduces ventral tegmental area dopamine neuronal hyperexcitability involving AKAP150 signaling following maternal deprivation in juvenile male rats10.1002/jnr.24613 ↗
15. Pharmacokinetics and acute toxicity of a histone deacetylase inhibitor, Scriptaid, and its neuroprotective effects in mice after intracranial hemorrhage10.2174/1871527319666191220111126 ↗
16. HDAC inhibition reduces white matter injury after intracerebral hemorrhage10.1177/0271678X20942613 ↗
17. HDAC6 is a microtubule-associated deacetylase10.1038/417455a ↗
18. HDAC6 is a target for protection and regeneration following injury in the nervous system10.1073/pnas.0907935106 ↗
19. Synthesis of a selective HDAC6 inhibitor active in neuroblasts10.1016/j.bmcl.2016.09.011 ↗
20. Structural and in vivo characterization of Tubastatin A, a widely used histone deacetylase 6 inhibitor10.1021/acsmedchemlett.9b00560 ↗
21. Electrospun nanofibers: new concepts, materials, and applications10.1021/acs.accounts.7b00218 ↗
22. PGS: gelatin nanofibrous scaffolds with tunable mechanical and structural properties for engineering cardiac tissues10.1016/j.biomaterials.2013.04.045 ↗
23. In vitro degradation and release profiles for electrospun polymeric fibers containing paracetanol10.1016/j.colsurfb.2008.06.021 ↗
24. Influence of polymer composition and drug loading procedure on dual drug release from PLGA: PEG electrospun fibers10.1016/j.ejps.2018.08.028 ↗
25. Poly (d, l-lactide)/polyethylene glycol micro/nanofiber mats as paclitaxel-eluting carriers: preparation and characterization of fibers, in vitro drug release, antiangiogenic activity and tumor recurrence prevention10.1016/j.msec.2019.01.046 ↗
26. Porous poly (lactic acid) based fibres as drug carriers in active dressings10.37190/ABB-01548-2020-03 ↗
27. Electrospun nanofibers for neural tissue engineering10.1039/B9NR00243J ↗
28. Nerve guidance conduits based on double-layered scaffolds of electrospun nanofibers for repairing the peripheral nervous system10.1021/am5018557 ↗
29. Amine-functionalized electrically conductive core–sheath MEH-PPV: PCL electrospun nanofibers for enhanced cell–biomaterial interactions10.1021/acsbiomaterials.8b00624 ↗
30. Combining electrospun nanofibers with cell-encapsulating hydrogel fibers for neural tissue engineering10.1080/09205063.2018.1479084 ↗
31. Elastic biodegradable poly (glycolide-co-caprolactone) scaffold for tissue engineering10.1002/jbm.a.10497 ↗
32. Effects of cardiac patches engineered with bone marrow-derived mononuclear cells and PGCL scaffolds in a rat myocardial infarction model10.1016/j.biomaterials.2006.09.009 ↗
33. Electrospun paclitaxel delivery system based on PGCL/PLGA in local therapy combined with brachytherapy10.1016/j.ijpharm.2021.120596 ↗
34. Silk fibroin as a functional biomaterial for tissue engineering10.3390/ijms22031499 ↗
35. Functionalized silk fibroin nanofibers as drug carriers: advantages and challenges10.1016/j.jconrel.2020.02.022 ↗
36. Stability and biodegradation of silk fibroin/hyaluronic acid nerve conduits10.1016/j.compositesb.2020.108222 ↗
37. Silk fibroin-magnetic hybrid composite electrospun fibers for tissue engineering applications10.1016/j.compositesb.2017.12.046 ↗
38. Triple-stimuli (pH/thermo/reduction) sensitive copolymers for intracellular drug delivery10.1039/c3tb00424d ↗
39. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
40. Spinal cord injury: a multisystem physiological impairment/dysfunction10.1016/j.neurol.2021.02.385 ↗
41. Pathophysiology of spinal cord injury10.1016/j.nec.2021.03.002 ↗
42. Current applications of poly (lactic acid) composites in tissue engineering and drug delivery10.1016/j.compositesb.2020.108238 ↗
43. HDAC6 in diseases of cognition and of neurons10.3390/cells10010012 ↗
44. HDAC family: what are the cancer relevant targets?10.1016/j.canlet.2008.08.016 ↗
45. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice10.3233/JAD-140066 ↗
46. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition10.1186/alzrt241 ↗
47. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury10.1016/j.neulet.2017.08.029 ↗
48. Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation
49. Flufenamic acid inhibits secondary hemorrhage and BSCB disruption after spinal cord injury10.7150/thno.25707 ↗
50. Deacetylation of Miro1 by HDAC6 blocks mitochondrial transport and mediates axon growth inhibition10.1083/jcb.201702187 ↗